Isolation of circulating tumor cells.
| Autor: | Edd JF; BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA., Mishra A; BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Smith KC; BendBio, Inc., Sharon, MA 02067, USA., Kapur R; BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; BendBio, Inc., Sharon, MA 02067, USA., Maheswaran S; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Haber DA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Bethesda, MD 20815, USA., Toner M; BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA.; Shriners Hospitals for Children, Boston, MA 02114, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | IScience [iScience] 2022 Jul 01; Vol. 25 (8), pp. 104696. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022). |
| DOI: | 10.1016/j.isci.2022.104696 |
| Abstrakt: | Circulating tumor cells (CTCs) enter the vasculature from solid tumors and disseminate widely to initiate metastases. Mining the metastatic-enriched molecular signatures of CTCs before, during, and after treatment holds unique potential in personalized oncology. Their extreme rarity, however, requires isolation from large blood volumes at high yield and purity, yet they overlap leukocytes in size and other biophysical properties. Additionally, many CTCs lack EpCAM that underlies much of affinity-based capture, complicating their separation from blood. Here, we provide a comprehensive introduction of CTC isolation technology, by analyzing key separation modes and integrated isolation strategies. Attention is focused on recent progress in microfluidics, where an accelerating evolution is occurring in high-throughput sorting of cells along multiple dimensions. Competing Interests: M.G.H. filed for patent protection for the CTC-iChip technology. M.T., R.K., D.H., and S.M. are founders of TellBio who are commercializing using the CTC-iChip 2. The authors declare that they have no other competing interests. (© 2022 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|